As of close of business last night, AVITA Medical Inc’s stock clocked out at $9.46, down -4.25% from its previous closing price of $9.88. On the day, 547137 shares were traded.
Ratios:
To gain a deeper understanding of RCEL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.46 and its Current Ratio is at 7.88. In the meantime, Its Debt-to-Equity ratio is 0.86 whereas as Long-Term Debt/Eq ratio is at 0.85.
On June 27, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $23.
On March 02, 2021, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $27.Piper Sandler initiated its Overweight rating on March 02, 2021, with a $27 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 28 ’24 when O’Toole David D bought 1,250 shares for $17.39 per share. The transaction valued at 21,738 led to the insider holds 18,734 shares of the business.
CORBETT JAMES sold 1,445 shares of RCEL for $19,204 on Dec 26 ’23. The CEO now owns 11,580 shares after completing the transaction at $13.29 per share. On Dec 13 ’23, another insider, COOK JEREMY CURNOCK, who serves as the Director of the company, sold 2,518 shares for $12.27 each. As a result, the insider received 30,896 and left with 20,596 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.69 while its Price-to-Book (P/B) ratio in mrq is 4.95.
Stock Price History:
Over the past 52 weeks, RCEL has reached a high of $21.70, while it has fallen to a 52-week low of $9.16.
Shares Statistics:
A total of 25.68M shares are outstanding, with a floating share count of 23.76M. Insiders hold about 4.35% of the company’s shares, while institutions hold 28.82% stake in the company.
Earnings Estimates
As of right now, FuelCell Energy, Inc. analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $127.17, with high estimates of $48.70 and low estimates of $9.46.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Consumer Cyclical.
